PVLA

William Blair initiated coverage of Palvella Therapeutics with a rating of Outperform

Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in Previously Treated Children with Cutaneous Venous Malformations QTORIN™ Rapamycin Has the Potential to Become the First FDA-Approved Therapy for Both Microcystic Lymphatic Malformations and Cutaneous Venous Malformations, Two Serious, Rare Diseases with No FDA-Approved Therapies  WAYNE, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a cl

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

144 - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that members of its management team will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on Tuesday, October 20, 2026, at 1:45 p.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay

Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S. WAYNE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and D

NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S. WAYNE, Pa., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Admi

Chardan Capital Markets resumed coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $240.00

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

Advisors bring biotechnology fundraising, drug development, and commercialization, as well as corporate strategy and M&A expertise to support the advancement of NB4168 and strategic corporate growth initiatives Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders. The Company has also engaged

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

144 - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and QTORIN™ trial investigator brings deep understanding of the unmet needs in serious, rare skin diseases including vascular anomalies Dr. Treat to lead medical strategy as Palvella moves QTORIN™ rapamycin toward potential approval and commercialization for microcystic lymphatic malformations and advances its pipeline of first-in-disease therapies WAYNE, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) --

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

144 - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor conferences. Cantor Global Healthcare Conference 2026Fireside Chat on Wednesday, September 9, 2026, at 1:35 p.m. ET H.C. Wainwright 28th Annual Global Investment ConferenceCorporate Presentation on

QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S.  FDA previously granted Breakthrough Therapy and Fast Track designations; QTORIN™ rapamycin has also received Orphan Drug designation Accelerating U.S. launch readiness for a potential commercial launch of QTORIN™ rapamycin in the first half of 2027, if approved WAYNE, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercia

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

SCHEDULE 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

SCHEDULE 13G - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's websit

S-8 - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026 Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for the second half of 2026 Topline results from the Phase 2 LOTU t